Regeneron Pharmaceuticals
REGN
1,202 hedge funds and large institutions have $46.9B invested in Regeneron Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 444 increasing their positions, 477 reducing their positions, and 206 closing their positions.
14% more call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.01B
7% less repeat investments, than reductions
Existing positions increased: 444 | Existing positions reduced: 477
2.66% less ownership
Funds ownership: 86.78% → 84.12% (-2.7%)
7% less funds holding
Funds holding: 1,290 → 1,202 (-88)
20% less funds holding in top 10
Funds holding in top 10: 15 → 12 (-3)
21% less capital invested
Capital invested by funds: $59.1B → $46.9B (-$12.2B)
36% less first-time investments, than exits
New positions opened: 132 | Existing positions closed: 206
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$838M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$338M |
| 3 |
Two Sigma Advisers
New York
|
+$215M |
| 4 |
BlackRock
New York
|
+$195M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$182M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.38B |
| 2 |
JP Morgan Chase
New York
|
-$959M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$786M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$460M |
| 5 |
Amundi
Paris,
France
|
-$394M |
REGN Hedge Fund Activity: Q2 2025 in Review
1,202 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2025, worth a combined $46.9B — down 21% from $59.1B a quarter earlier.
Sellers outnumbered buyers: 206 funds closed out of REGN and 132 opened new positions — a net loss of 74 holders — while 477 trimmed existing stakes and 444 added.
The largest buyer was Dodge & Cox, adding an estimated $838M. The largest seller was Fidelity Investments, cutting an estimated $2.38B.
- 1,202 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2025, down from 1,290 in Q1 2025.
- Funds reported $46.9B of Regeneron Pharmaceuticals stock for Q2 2025, down 21% quarter-over-quarter.
- 132 funds opened new Regeneron Pharmaceuticals positions in Q2 2025 and 206 closed out, a net change of -74 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2025 was Dodge & Cox, an estimated $838M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2025 was Fidelity Investments, an estimated $2.38B sold.
Based on aggregated 13F filings for Q2 2025.